{
    "clinical_study": {
        "@rank": "154539", 
        "arm_group": [
            {
                "arm_group_label": "OZURDEX intraocular implant", 
                "arm_group_type": "Experimental", 
                "description": "OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg"
            }, 
            {
                "arm_group_label": "Steroid plus NSAID eye drop combination therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "NSAID eye drop: Acular LS Steriod eye drop: Pred Forte"
            }
        ], 
        "brief_summary": {
            "textblock": "There is a need to find an effective therapy for diabetic patients who develop macular edema\n      after cataract surgery. The objective of this study is to assess the safety and efficacy of\n      the OZURDEX\u00ae intraocular implant in patients with diabetes mellitus, who develop macular\n      edema after cataract surgery."
        }, 
        "brief_title": "A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX\u00ae Intraocular Implant in Patients With Diabetes Mellitus", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Edema After Cataract Surgery in Patients With Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Macular Edema", 
                "Cataract", 
                "Capsule Opacification"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has diagnosis of Diabetes Mellitus, Type I or II.\n\n          -  Patient has experienced the development of macular edema following cataract surgery\n             in at least one eye.\n\n          -  Patient has had cataract surgery within 90 days prior to the screening visit.\n\n        Exclusion Criteria:\n\n          -  Patient has other significant ocular disease in study eye, including glaucoma.\n\n          -  Patient has any active infection in the study eye.\n\n          -  Patient has uncontrolled systemic illness (i.e., uncontrolled blood pressure,\n             uncontrolled diabetes mellitus).\n\n          -  Patient has experienced a significant increase in intraocular pressure following a\n             prior treatment with topical or intravitreal steroidal medication.\n\n          -  Patient has received the OZURDEX\u00ae implant before in the study eye."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673191", 
            "org_study_id": "RCA2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "OZURDEX intraocular implant", 
                "intervention_name": "Dexamethasone intravitreal implant", 
                "intervention_type": "Drug", 
                "other_name": "OZURDEX"
            }, 
            {
                "arm_group_label": "Steroid plus NSAID eye drop combination therapy", 
                "intervention_name": "Steroid plus NSAID eye drop combination therapy", 
                "intervention_type": "Drug", 
                "other_name": "Acular LS and Pred Forte"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents, Non-Steroidal", 
                "Tetrahydrozoline", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Prednisolone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "contact": {
                "email": "smobley@retinalconsultantsaz.com", 
                "last_name": "Sarah Mobley", 
                "phone": "602-222-2221", 
                "phone_ext": "4152"
            }, 
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85014"
                }, 
                "name": "Retinal Consultants of Arizona"
            }, 
            "investigator": [
                {
                    "last_name": "Pravin Dugel, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Derek Kunimoto, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Edward Quinlan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jaime Gaitan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Goldenberg, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Karim Jamal, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sachin Mehta, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Madhavi Kurli, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX\u00ae Intraocular Implant in Patients With Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Retinal Consultants of Arizona", 
            "last_name": "Pravin U Dugel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with significant decrease in OCT (e.g., 50-100 \u00b5m) following treatment with OZURDEX\u00ae.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673191"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Retinal Consultants of Arizona", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Retinal Consultants of Arizona", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}